Cyclopharm Limited

CYC

AU000000CYC5

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 08:02:08 2024-04-25 pm EDT			5-day change	1st Jan Change
1.75 ^AUD	0.00%		-1.69%	-9.09%

Mar. 19	Cyclopharm's Technegas Device Carries Out Imaging of First US Patients	MT
Mar. 18	Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index	CI

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

February 19, 2023 at 10:08 pm EST

Cyclopharm Limited announced dividend of AUD 0.00500000 a period of six months ended December 31, 2022 with record date of March 28, 2023, Ex date of March 27, 2023 and Payable on April 4, 2023.

Latest news about Cyclopharm Limited

Cyclopharm's Technegas Device Carries Out Imaging of First US Patients	Mar. 19	MT
Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index	Mar. 17	CI
Cyclopharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director	Feb. 18	CI
Cyclopharm Appoints CFO; Shares Rise 3%	Feb. 12	MT
Cyclopharm Signs First US Deal for Inhalable Imaging Product	Dec. 05	MT
Argenica Therapeutics Appoints Nonexecutive Chair	Nov. 29	MT
Cyclopharm Advances Rollout of Imaging Drug in the US	Nov. 15	MT
Cyclopharm Says U.S. SNMMI Confirms FDA Nod for Technegas	23-10-04	MT
Cyclopharm Secures US FDA Clearance for Inhalable Imaging Product; Shares Rise 5%	23-10-02	MT
Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023	23-08-21	CI
Cyclopharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
US FDA Completes Site Inspection for Cyclopharm’s Technegas Facility	23-08-08	MT
Australian Shares Retreat Ahead of Federal Budget	23-05-09	MT
Cyclopharm Secures US FDA Inspection Date for Imaging Drug Production Facility; Shares Rise 4%	23-05-09	MT
US FDA Confirms Receipt of Cyclopharm's Response Submission for Inhalable Imaging Agent	23-04-24	MT
Cyclopharm Takes Over Denmark-based DuPharma ApS	23-04-19	MT
Cyclopharm Limited acquired Dupharma Aps.	23-04-19	CI
Cyclopharm Limited announced that it expects to receive AUD 0.218 million in funding	23-04-16	CI
Cyclopharm Files Formal Reply to US FDA for Inhalable Imaging Agent	23-03-30	MT
Cyclopharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-19	CI
Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023	23-02-19	CI
Cyclopharm Receives $1.1 Million R&D Tax Rebate	22-11-29	MT
Cyclopharm Limited Appoints Gregory King as A Non-Executive Director	22-09-26	CI
Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director	22-08-31	CI

Cyclopharm Limited is an Australia-based health technology company. The Companyâs principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. Its subsidiaries include Cyclomedica Europe Limited, Cyclomedica Australia Pty Limited and Cyclomedica Canada Limited.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Cyclopharm Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.141 USD

Average target price

3.004 USD

Spread / Average Target

+163.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
CYCLOPHARM LIMITED	-9.09%	107M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology